Cellosaurus logo
expasy logo

Cellosaurus Mahlavu (CVCL_0405)

[Text version]
Cell line name Mahlavu
Synonyms MAHLAVU
Accession CVCL_0405
Resource Identification Initiative To cite this cell line use: Mahlavu (RRID:CVCL_0405)
Comments Part of: Liver Cancer Model Repository (LIMORE).
Population: African.
Doubling time: 22.5 hours (CelloPub=CLPUB00076); 52.01 hours (PubMed=31378681).
Omics: Deep exome analysis.
Omics: Genome sequenced.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Transcriptome analysis by RNAseq.
Misspelling: Malhavu; Note=Occasionally.
Derived from site: In situ; Liver; UBERON=UBERON_0002107.
Sequence variations
Disease Hepatocellular carcinoma (NCIt: C3099)
Hepatocellular carcinoma (ORDO: Orphanet_88673)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): CLS; PubMed=31378681

Markers:
AmelogeninX
CSF1PO7,11
D2S133819,22
D3S135817
D5S81812
D6S104312
D7S82010,11
D8S117911,14
D12S39118
D13S31712,13
D16S53911
D18S5115
D19S43311,14
D21S1131.2,32.2
FGA28
Penta D9,11
Penta E8,11
TH017
TPOX8,10
vWA15

Run an STR similarity search on this cell line
Web pages https://lccl.zucmanlab.com/hcc/cellLines/Mahlavu
Publications

CLPUB00076
Prozesky O.W., Brits C., Grabow W.O.K.
In vitro culture of cell lines from Australia antigen positive and negative hepatoma patients.
(In) Liver; Saunders S.J., Terblanche J. (eds.); pp.358-360; Pitman Medical Books; London (1973)

CLPUB00575
Prozesky O.W., Lecatsas G.
Scanning electron microscopy of a human hepatoma cell line.
S. Afr. Med. J. 49:1061-1062(1975)

PubMed=179808; DOI=10.1111/j.1432-1033.1976.tb10294.x
Grimm J.
The influence of insulin on various enzyme activities in human and rat hepatoma cells.
Eur. J. Biochem. 64:249-253(1976)

PubMed=6268737; DOI=10.1099/0022-1317-53-1-105
Oefinger P.E., Bronson D.L., Dreesman G.R.
Induction of hepatitis B surface antigen in human hepatoma-derived cell lines.
J. Gen. Virol. 53:105-113(1981)

PubMed=6275024; DOI=10.1099/0022-1317-57-1-95
Koshy R., Maupas P., Muller R., Hofschneider P.H.
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.
J. Gen. Virol. 57:95-102(1981)

DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.-J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)

PubMed=8224613; DOI=10.1096/fasebj.7.14.8224613
Puisieux A., Galvin K., Troalen F., Bressac B., Marcais C., Galun E., Ponchel F., Yakicier C., Ji J.-W., Ozturk M.
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines.
FASEB J. 7:1407-1413(1993)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
HLA expression in hepatocellular carcinoma cell lines.
Clin. Exp. Immunol. 97:328-333(1994)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218.1-2218.7(2013)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)

PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)

PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)

Cross-references
Cell line collections (Providers) CLS; 300473
Cell line databases/resources MCCL; MCC:0000299
cancercelllines; CVCL_0405
LIMORE; Mahlavu
Anatomy/cell type resources BTO; BTO:0004471
Chemistry resources ChEMBL-Cells; CHEMBL4295417
ChEMBL-Targets; CHEMBL4296473
PubChem_Cell_line; CVCL_0405
Encyclopedic resources Wikidata; Q54903975
Gene expression databases GEO; GSM2551578
Polymorphism and mutation databases Cosmic; 873398
Cosmic; 948064
Cosmic; 979727
Cosmic; 1019317
Cosmic; 2162534
Cosmic; 2321039
IARC_TP53; 2183
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number24